Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 v

Toni Choueiri, MD· @DrChoueiri · X·2026-10-25 23:48· 1 day agoScore70

Body

Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 vs 12.0 mo (HR 0.56; p=0.0005). ORR 58% vs 32%.

#ESMO26 #LungCancer @myESMO @OncoAlert

135 views · 5 likes · 2 reposts · 0 replies

Conference abstracts

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

Source: Toni Choueiri, MD · x.com